HRP20150410T1 - Novi pripravci za terapiju esencijalne trombocitemije - Google Patents
Novi pripravci za terapiju esencijalne trombocitemije Download PDFInfo
- Publication number
- HRP20150410T1 HRP20150410T1 HRP20150410TT HRP20150410T HRP20150410T1 HR P20150410 T1 HRP20150410 T1 HR P20150410T1 HR P20150410T T HRP20150410T T HR P20150410TT HR P20150410 T HRP20150410 T HR P20150410T HR P20150410 T1 HRP20150410 T1 HR P20150410T1
- Authority
- HR
- Croatia
- Prior art keywords
- acid
- composition according
- pharmaceutical composition
- amount
- pharmaceutical preparation
- Prior art date
Links
- 208000032027 Essential Thrombocythemia Diseases 0.000 title claims 2
- 239000000203 mixture Substances 0.000 title claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- OTBXOEAOVRKTNQ-UHFFFAOYSA-N anagrelide Chemical compound N1=C2NC(=O)CN2CC2=C(Cl)C(Cl)=CC=C21 OTBXOEAOVRKTNQ-UHFFFAOYSA-N 0.000 claims 6
- 229960001694 anagrelide Drugs 0.000 claims 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims 6
- 239000002253 acid Substances 0.000 claims 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 3
- 229920002125 Sokalan® Polymers 0.000 claims 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 3
- 239000002245 particle Substances 0.000 claims 3
- 239000004584 polyacrylic acid Substances 0.000 claims 3
- 229920000642 polymer Polymers 0.000 claims 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 claims 2
- 235000015165 citric acid Nutrition 0.000 claims 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims 1
- 239000001361 adipic acid Substances 0.000 claims 1
- 235000011037 adipic acid Nutrition 0.000 claims 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims 1
- 239000011668 ascorbic acid Substances 0.000 claims 1
- 229960005070 ascorbic acid Drugs 0.000 claims 1
- 235000010323 ascorbic acid Nutrition 0.000 claims 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims 1
- 235000010980 cellulose Nutrition 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 239000001530 fumaric acid Substances 0.000 claims 1
- 235000011087 fumaric acid Nutrition 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 235000019359 magnesium stearate Nutrition 0.000 claims 1
- 239000001630 malic acid Substances 0.000 claims 1
- 235000011090 malic acid Nutrition 0.000 claims 1
- 229920002401 polyacrylamide Polymers 0.000 claims 1
- 239000011975 tartaric acid Substances 0.000 claims 1
- 235000002906 tartaric acid Nutrition 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Paints Or Removers (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Claims (13)
1. Farmaceutski pripravak bez acidorezistentne ovojnice koji sadrži anagrelid HCl, pH neovisni polimer i farmaceutski prihvatljivu vodotopljivu kiselinu, pri čemu je pH neovisni polimer izabran iz skupine koja se sastoji od poliakrilne kiseline, derivata celuloze ili poliakrilamida, posebice Karbopol™ i pri čemu je količina pH neovisnog polimera između 1,5 i 2,5 masenog udjela anagrelida(w/w).
2. Farmaceutski pripravak u skladu sa zahtjevom 1 u kojem je anagrelid HCl u obliku čestica, pri čemu je najmanje 90% od navedenih čestica promjera manjeg od 10 µm.
3. Farmaceutski pripravak u skladu sa zahtjevom 1 ili 2 koji sadrži anagrelid HCl u količini od 0,5 do 5 mg, poželjno između 1,5 i 3 mg, optimalno između 2 i 3 mg, naročito u količini od 2,3 mg.
4. Farmaceutski pripravak u skladu sa bilo kojim od zahtjeva 1 do 3 u kojem je poliakrilna kiselina prisutna u količini između 1 i 10 mg, poželjno između 2,5 i 5 mg, optimalno između 3 i 4 mg.
5. Farmaceutski pripravak u skladu sa bilo kojim od zahtjeva 1 do 4 u kojem je farmaceutski prihvatljiva vodotopljiva kiselina izabrana iz skupine koja se sastoji od adipinske kiseline, askorbinske kiseline, limunske kiseline, fumarne kiseline, jabučne kiseline, jantarne kiseline, vinske kiseline i njihovih mješavina.
6. Farmaceutski pripravak u skladu sa bilo kojim od zahtjeva 1 do 5 u kojem je vodotopljiva kiselina prisutna u količini između 5 i 40 mg, poželjno između 10 i 20 mg, optimalno između 15 i 19 mg.
7. Farmaceutski pripravak u skladu sa bilo kojim od zahtjeva 1 do 6 u kojem anagrelid ima osnovnu veličinu čestica od otprilike 5 µm.
8. Farmaceutski pripravak u skladu sa bilo kojim od zahtjeva 1 do 7 koji sadrži mikrokristaliničnu celulozu.
9. Farmaceutski pripravak u skladu sa bilo kojim od zahtjeva 1 do 8 u kojem je mikrokristalinična celuloza prisutna u količini između 10 i 150 mg, poželjno između 25 i 100 mg, optimalno između 70 i 80 mg.
10. Farmaceutski pripravak u skladu sa bilo kojim od zahtjeva 1 do 9 koji ima in vitro oslobađanje od najmanje 45% nakon 8 sati.
11. Farmaceutski pripravak u skladu sa bilo kojim od zahtjeva 1 do 10 koji sadrži anagrelid HCl, poliakrilnu kiselinu, limunsku kiselinu, mikrokristaliničnu celulozu i magnezijev stearat.
12. Farmaceutski pripravak u skladu sa bilo kojim od zahtjeva 1 do 11 koji je u obliku tablete.
13. Farmaceutski pripravak u skladu sa bilo kojim od zahtjeva 1 do 12 za uporabu u terapiji esencijalne trombocitemije.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10157772 | 2010-03-25 | ||
| PCT/EP2011/054628 WO2011117391A2 (en) | 2010-03-25 | 2011-03-25 | Novel composition for treatment of essential thrombocythemia |
| EP11710202.0A EP2549983B1 (en) | 2010-03-25 | 2011-03-25 | Novel composition for treatment of essential thrombocythemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20150410T1 true HRP20150410T1 (hr) | 2015-06-05 |
Family
ID=42732455
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20150410TT HRP20150410T1 (hr) | 2010-03-25 | 2015-04-13 | Novi pripravci za terapiju esencijalne trombocitemije |
Country Status (23)
| Country | Link |
|---|---|
| US (4) | US20130028945A1 (hr) |
| EP (1) | EP2549983B1 (hr) |
| JP (1) | JP5836357B2 (hr) |
| AU (1) | AU2011231557B2 (hr) |
| BR (1) | BR112012024239A2 (hr) |
| CA (1) | CA2794237C (hr) |
| CY (1) | CY1116396T1 (hr) |
| DK (1) | DK2549983T3 (hr) |
| EA (1) | EA027576B1 (hr) |
| ES (1) | ES2535480T3 (hr) |
| HR (1) | HRP20150410T1 (hr) |
| IL (1) | IL222072A (hr) |
| ME (1) | ME02118B (hr) |
| MX (1) | MX2012011051A (hr) |
| NZ (1) | NZ602366A (hr) |
| PL (1) | PL2549983T3 (hr) |
| PT (1) | PT2549983E (hr) |
| RS (1) | RS53960B1 (hr) |
| SG (1) | SG184227A1 (hr) |
| SI (1) | SI2549983T1 (hr) |
| SM (1) | SMT201500119B (hr) |
| UA (1) | UA110933C2 (hr) |
| WO (1) | WO2011117391A2 (hr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG184227A1 (en) * | 2010-03-25 | 2012-10-30 | Aop Orphan Pharmaceuticals Ag | Novel composition for treatment of essential thrombocythemia |
| EP3236967B1 (en) * | 2014-12-22 | 2019-10-16 | SUDA Pharmaceuticals Ltd | Prevention and treatment of metastatic disease in thrombocytotic cancer patients |
| EP4183430A1 (en) | 2021-11-18 | 2023-05-24 | Koninklijke Philips N.V. | Sensor arrangement for a breast pump device and breast pump device using the sensor arrangement |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6287599B1 (en) * | 2000-12-20 | 2001-09-11 | Shire Laboratories, Inc. | Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles |
| DE60326709D1 (de) * | 2002-04-29 | 2009-04-30 | Supernus Pharmaceuticals Inc | Pharmazeutische formulierungen mit verbesserter bioverfügbarkeit |
| US7993654B2 (en) * | 2002-12-23 | 2011-08-09 | Beiersdorf Ag | Self-adhesive polymer matrix containing sea algae extract |
| WO2005107719A2 (en) * | 2004-05-06 | 2005-11-17 | Sandoz Ag | Pharmaceutical composition comprising hydrophobic drug having improved solubility |
| JP2010532746A (ja) * | 2007-01-25 | 2010-10-14 | パナセア バイオテック リミテッド | 放出調節医薬組成物およびその製造方法 |
| GB2462022B (en) * | 2008-06-16 | 2011-05-25 | Biovascular Inc | Controlled release compositions of agents that reduce circulating levels of platelets and methods thereof |
| AT10562U3 (de) * | 2008-12-05 | 2010-01-15 | Aop Orphan Pharmaceuticals Ag | Neuartige zusammensetzung zur behandlung einer essenziellen thrombozytämie |
| US8465770B2 (en) * | 2008-12-24 | 2013-06-18 | Synthon Bv | Low dose controlled release tablet |
| SG184227A1 (en) * | 2010-03-25 | 2012-10-30 | Aop Orphan Pharmaceuticals Ag | Novel composition for treatment of essential thrombocythemia |
-
2011
- 2011-03-25 SG SG2012070678A patent/SG184227A1/en unknown
- 2011-03-25 SI SI201130494T patent/SI2549983T1/sl unknown
- 2011-03-25 JP JP2013500526A patent/JP5836357B2/ja not_active Expired - Fee Related
- 2011-03-25 PT PT117102020T patent/PT2549983E/pt unknown
- 2011-03-25 US US13/637,014 patent/US20130028945A1/en not_active Abandoned
- 2011-03-25 UA UAA201212238A patent/UA110933C2/uk unknown
- 2011-03-25 EA EA201201329A patent/EA027576B1/ru not_active IP Right Cessation
- 2011-03-25 BR BR112012024239A patent/BR112012024239A2/pt not_active IP Right Cessation
- 2011-03-25 WO PCT/EP2011/054628 patent/WO2011117391A2/en active Application Filing
- 2011-03-25 MX MX2012011051A patent/MX2012011051A/es active IP Right Grant
- 2011-03-25 CA CA2794237A patent/CA2794237C/en not_active Expired - Fee Related
- 2011-03-25 DK DK11710202.0T patent/DK2549983T3/da active
- 2011-03-25 ES ES11710202.0T patent/ES2535480T3/es active Active
- 2011-03-25 ME MEP-2015-61A patent/ME02118B/me unknown
- 2011-03-25 AU AU2011231557A patent/AU2011231557B2/en not_active Ceased
- 2011-03-25 NZ NZ602366A patent/NZ602366A/en not_active IP Right Cessation
- 2011-03-25 PL PL11710202T patent/PL2549983T3/pl unknown
- 2011-03-25 RS RS20150284A patent/RS53960B1/en unknown
- 2011-03-25 EP EP11710202.0A patent/EP2549983B1/en not_active Revoked
-
2012
- 2012-09-23 IL IL222072A patent/IL222072A/en active IP Right Grant
-
2014
- 2014-11-26 US US14/555,256 patent/US20150086637A1/en not_active Abandoned
-
2015
- 2015-04-13 HR HRP20150410TT patent/HRP20150410T1/hr unknown
- 2015-05-20 SM SM201500119T patent/SMT201500119B/xx unknown
- 2015-05-29 CY CY20151100475T patent/CY1116396T1/el unknown
-
2016
- 2016-10-21 US US15/331,798 patent/US9782413B2/en not_active Expired - Fee Related
-
2017
- 2017-10-04 US US15/725,226 patent/US20180028538A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2794237A1 (en) | 2011-09-29 |
| AU2011231557B2 (en) | 2016-05-26 |
| RS53960B1 (en) | 2015-08-31 |
| MX2012011051A (es) | 2013-01-29 |
| US20170035768A1 (en) | 2017-02-09 |
| PL2549983T3 (pl) | 2015-08-31 |
| EP2549983B1 (en) | 2015-03-04 |
| SG184227A1 (en) | 2012-10-30 |
| AU2011231557A1 (en) | 2012-10-04 |
| US20180028538A1 (en) | 2018-02-01 |
| EP2549983A2 (en) | 2013-01-30 |
| ES2535480T3 (es) | 2015-05-12 |
| ME02118B (me) | 2015-10-20 |
| CA2794237C (en) | 2017-09-26 |
| JP2013523616A (ja) | 2013-06-17 |
| DK2549983T3 (da) | 2015-06-01 |
| US20130028945A1 (en) | 2013-01-31 |
| JP5836357B2 (ja) | 2015-12-24 |
| CY1116396T1 (el) | 2017-02-08 |
| IL222072A (en) | 2017-12-31 |
| US20150086637A1 (en) | 2015-03-26 |
| UA110933C2 (uk) | 2016-03-10 |
| SI2549983T1 (sl) | 2015-06-30 |
| US9782413B2 (en) | 2017-10-10 |
| WO2011117391A3 (en) | 2012-01-19 |
| NZ602366A (en) | 2014-08-29 |
| PT2549983E (pt) | 2015-06-17 |
| SMT201500119B (it) | 2015-07-09 |
| EA027576B1 (ru) | 2017-08-31 |
| BR112012024239A2 (pt) | 2016-07-12 |
| EA201201329A1 (ru) | 2013-02-28 |
| WO2011117391A2 (en) | 2011-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018253545A1 (en) | Microcrystalline diketopiperazine compositions and methods | |
| UA105078C2 (uk) | Фармацевтична композиція, яка містить тетрагідрофолієву кислоту | |
| IL309564A (en) | Preparations containing apixaban | |
| EP3626253A3 (en) | Stable formulations of linaclotide | |
| WO2011076749A3 (en) | Solid pharmaceutical dosage form of ticagrelor | |
| MX2014001556A (es) | Composicion farmaceutica de sabor enmascarado. | |
| JP2011178784A5 (hr) | ||
| RS53995B1 (en) | NEW ABUSE-RESISTANT PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF OPIOID SUBSTANCE | |
| HRP20201386T1 (hr) | Farmaceutska kompozicija, koja sadrži čestice vezivnog sredstva za fosfat | |
| GEP201706780B (en) | Substituted 2-aza-bicyclo [2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c | |
| NZ600640A (en) | Abuse-resistant formulations | |
| NZ595663A (en) | Immediate release pharmaceutical compositions comprising oxycodone and naloxone | |
| IL273300B1 (en) | High dose valbenazine formulation and related preparations, methods and kits | |
| EA201491674A1 (ru) | Новые фармацевтические композиции | |
| JP2016516698A5 (hr) | ||
| RU2015128609A (ru) | Перенасыщенные стабилизированные наночастицы для слаборастворимых лекарственных средств | |
| HRP20150410T1 (hr) | Novi pripravci za terapiju esencijalne trombocitemije | |
| HRP20161340T1 (hr) | Formulacije darunavira | |
| JP2018527305A5 (hr) | ||
| WO2010038688A1 (ja) | アトルバスタチン経口投与用粒子状医薬組成物 | |
| NZ603199A (en) | Orally disintegrating tablet containing acarbose | |
| NZ714517A (en) | Delayed release cysteamine bead formulation | |
| EP2384746A3 (en) | Dual release oral tablet compositions of dexlansoprazole | |
| IL207928A (en) | Pharmacotherapeutic agent that contains an active drug (mtx) and helps 2, 2-anhydropyrimidine to reduce and use mtx toxicity | |
| HRP20110023T1 (hr) | Smanjenje prekomjerne težine ili pretilosti |